Literature DB >> 17495126

Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.

Marcus Winkler1, Damian Stephan, Susanne Bieger, Petra Kühner, Felix Wolff, Ulrich Quast.   

Abstract

ATP-sensitive K(+) (K(ATP)) channels are composed of pore-forming subunits (Kir6.x) and of regulatory subunits, the sulfonylurea receptors (SURx). Subtypes of K(ATP) channels are expressed in different organs. The sulfonylureas and glinides (insulinotropes) close the K(ATP) channel in pancreatic beta-cells and stimulate insulin secretion. The insulinotrope binding site of the pancreatic channel (Kir6.2/SUR1) consists of two overlapping (sub)-sites, site A, located on SUR1 and containing Ser1237 (which in SUR2 is replaced by Tyr1206), and site B, formed by SUR1 and Kir6.2. Insulinotropes bind to the A-, B-, or A + B-site(s) and are grouped accordingly. A-ligands are highly selective in closing the pancreatic channel, whereas B-ligands are nonselective and insensitive to the mutation S1237Y. We have examined the binding of insulinotropes representative of the three groups in [(3)H]glibenclamide competition experiments to determine the contribution of Kir6.x to binding affinity, the effect of the mutation Y1206S in site A of SUR2, and the subtype selectivity of the compounds. The results show that the bipartite nature of the SUR1 binding site applies also to SUR2. Kir6.2 as part of the B-site may interact directly or allosterically with structural elements common to all insulinotropes, i.e., the negative charge and/or the adjacent phenyl ring. The B-site confers a moderate subtype selectivity on B-ligands. The affinity of B-ligands is altered by the mutation SUR2(Y1206S), suggesting that the mutation affects the binding chamber of SUR2 as a whole or subsite A, including the region where the subsites overlap.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495126     DOI: 10.1124/jpet.107.123224

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  The molecular genetics of sulfonylurea receptors in the pathogenesis and treatment of insulin secretory disorders and type 2 diabetes.

Authors:  Veronica Lang; Nermeen Youssef; Peter E Light
Journal:  Curr Diab Rep       Date:  2011-12       Impact factor: 4.810

2.  Incomplete dissociation of glibenclamide from wild-type and mutant pancreatic K ATP channels limits their recovery from inhibition.

Authors:  U Russ; P Kühner; R Prager; D Stephan; J Bryan; U Quast
Journal:  Br J Pharmacol       Date:  2009-01-13       Impact factor: 8.739

3.  An abundant, truncated human sulfonylurea receptor 1 splice variant has prodiabetic properties and impairs sulfonylurea action.

Authors:  Diethart Schmid; Michael Stolzlechner; Albin Sorgner; Caterina Bentele; Alice Assinger; Peter Chiba; Thomas Moeslinger
Journal:  Cell Mol Life Sci       Date:  2011-06-14       Impact factor: 9.261

4.  Substitution of the Walker A lysine by arginine in the nucleotide-binding domains of sulphonylurea receptor SUR2B: effects on ligand binding and channel activity.

Authors:  Tobias Amann; Sophie Schell; Petra Kühner; Marcus Winkler; Mathias Schwanstecher; Ulrich Russ; Ulrich Quast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-30       Impact factor: 3.000

5.  Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel.

Authors:  Petra Kühner; Renate Prager; Damian Stephan; Ulrich Russ; Marcus Winkler; David Ortiz; Joseph Bryan; Ulrich Quast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-15       Impact factor: 3.000

6.  Role of the amino-terminal transmembrane domain of sulfonylurea receptor SUR2B for coupling to K(IR)6.2, ligand binding, and oligomerization.

Authors:  Marcus Winkler; Petra Kühner; Ulrich Russ; David Ortiz; Joseph Bryan; Ulrich Quast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-17       Impact factor: 3.000

Review 7.  Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea.

Authors:  S Seino
Journal:  Diabetologia       Date:  2012-05-04       Impact factor: 10.122

8.  Analysis of two KCNJ11 neonatal diabetes mutations, V59G and V59A, and the analogous KCNJ8 I60G substitution: differences between the channel subtypes formed with SUR1.

Authors:  Marcus Winkler; Rebekka Lutz; Ulrich Russ; Ulrich Quast; Joseph Bryan
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

Review 9.  Pharmacological chaperones of ATP-sensitive potassium channels: Mechanistic insight from cryoEM structures.

Authors:  Gregory M Martin; Min Woo Sung; Show-Ling Shyng
Journal:  Mol Cell Endocrinol       Date:  2019-12-09       Impact factor: 4.102

10.  Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel.

Authors:  Kevin S C Hamming; Daniel Soliman; Laura C Matemisz; Omid Niazi; Yiqiao Lang; Anna L Gloyn; Peter E Light
Journal:  Diabetes       Date:  2009-07-08       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.